PHASEBIO PHARMACEUTICALS INC's ticker is PHAS and the CUSIP is 717224109. A total of 58 filers reported holding PHASEBIO PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $21,000 | -44.7% | 14,587 | +0.4% | 0.00% | -100.0% |
| Q4 2021 | $38,000 | -29.6% | 14,536 | -15.4% | 0.00% | 0.0% |
| Q3 2021 | $54,000 | +3.8% | 17,172 | +21.1% | 0.00% | 0.0% |
| Q2 2021 | $52,000 | +79.3% | 14,179 | +57.6% | 0.00% | 0.0% |
| Q1 2021 | $29,000 | -42.0% | 8,995 | -37.0% | 0.00% | 0.0% |
| Q4 2020 | $50,000 | -12.3% | 14,283 | -13.1% | 0.00% | -50.0% |
| Q3 2020 | $57,000 | +42.5% | 16,434 | +89.9% | 0.00% | +100.0% |
| Q2 2020 | $40,000 | – | 8,655 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 1,607,044 | $4,194,000 | 0.48% |
| NEA Management Company, LLC | 6,643,704 | $17,340,000 | 0.35% |
| Platform Technology Partners | 251,723 | $657,000 | 0.29% |
| DAFNA Capital Management LLC | 378,611 | $988,000 | 0.25% |
| Avidity Partners Management LP | 4,405,000 | $11,497,000 | 0.24% |
| Endurant Capital Management LP | 360,078 | $940,000 | 0.23% |
| Rock Springs Capital Management LP | 2,581,299 | $6,737,000 | 0.16% |
| RA Capital Management | 2,850,000 | $7,439,000 | 0.13% |
| New Legacy Group, LLC | 240,575 | $628,000 | 0.12% |
| XTX Topco Ltd | 15,574 | $41,000 | 0.02% |